(News Bulletin 247) – The shareholders of Erytech Pharma like those of Pherecydes Pharma have approved the merger between the two companies on the basis of an exchange parity of four Pherecydes shares for 15 Erytech shares.
At the joint general meeting held on Friday morning, Erytech shareholders voted in favor of the merger which should give rise to the ‘Phaxiam Therapeutics’ group.
The percentage of votes collected in favor of the operation, which will become retroactive in accounting and tax terms to January 1, 2023, has not been specified.
Last week, the investment fund Akkadian Partners announced its intention not to participate in the general meeting of Erytech, in order to oppose a “massive” dilution of 50% of its participation.
The objective of the merger and to create a world leader in phage therapy, an innovative approach based on the use of phages, natural viruses that kill resistant and dangerous bacteria.
The Pherecydes shares, now suspended, will be delisted at the end of the trading day on June 28.
The new Phaxiam Therapeutics shares resulting from the merger will be admitted to trading on compartment C of Euronext Paris from June 29.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
